Sand Grove Capital Management LLP Takes Position in Kenvue Inc. $KVUE

Sand Grove Capital Management LLP bought a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, HoldingsChannel reports. The firm bought 1,270,766 shares of the company’s stock, valued at approximately $21,921,000. Kenvue accounts for 7.4% of Sand Grove Capital Management LLP’s investment portfolio, making the stock its 10th biggest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in KVUE. Physician Wealth Advisors Inc. lifted its stake in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the period. Elyxium Wealth LLC purchased a new position in shares of Kenvue in the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. lifted its stake in shares of Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares during the period. Leonteq Securities AG purchased a new position in shares of Kenvue in the 4th quarter valued at approximately $45,000. Finally, Quarry LP purchased a new position in shares of Kenvue in the 4th quarter valued at approximately $76,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE opened at $18.44 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The firm has a market capitalization of $35.40 billion, a P/E ratio of 21.69, a PEG ratio of 1.38 and a beta of 0.54. The business has a fifty day moving average of $17.48 and a 200 day moving average of $17.56.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. During the same quarter in the previous year, the company posted $0.24 earnings per share. Kenvue’s revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.5%. Kenvue’s payout ratio is presently 97.65%.

Insider Activity at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.59% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on KVUE. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. UBS Group lowered their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Barclays lowered their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Finally, Canaccord Genuity Group boosted their price target on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.